arrow
K

Kornélia Polyák

Dana-Farber Cancer Institute
H指数:106
被引数:7.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Histone H4 lysine 20 tri-methylation safeguards breast cancer lineage fidelity and unfolded protein response

组蛋白H4赖氨酸20三甲基化保护乳腺癌谱系保真度和未折叠蛋白反应

2026-08-220
OA
TLSB-06 MULTIPLEXED IMMUNOSTAINING IDENTIFIES EPIGENETIC DEPENDENCY OF BREAST CANCER BRAIN METASTASIS

TLSB-06 多标记免疫组化染色鉴定乳腺癌脑转移的表观遗传依赖性

2026-08-070
OA
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis

HER2DX和早期HER2阳性乳腺癌的生存结局:一项基于个体患者水平的荟萃分析

2025-07-140
PRE
Associations of circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with the expression of stem cell markers in benign breast tissue

循环胰岛素样生长因子-1和胰岛素样生长因子结合蛋白-3与良性乳腺组织中干细胞标志物表达的关系

2025-04-070
OA
ZBTB7A is a modulator of KDM5-driven transcriptional networks in basal breast cancer
2024-12-010
PRE
PIK3CA inhibition in models of proliferative glomerulonephritis and lupus nephritis
2024-06-062
OAAI
Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx- mediated resistance to HER2targeting therapies
2024-05-062
OAAI
Event-free Survival by Residual Cancer Burden (RCB) and Intratumor HER2 Heterogeneity after Neoadjuvant T-DM1 and Pertuzumab for Early-stage HER2-positive Breast Cancer
2024-05-020
PRE
Investigating HER2DX genomic assay concordance within HER2-positive breast cancer
2024-05-020
PRE
Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments(vol 21, pg 879, 2019)
2024-03-050
OA
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer
2024-03-018
OAAI
HER2 heterogeneity and treatment response- associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial

NCT02326974临床试验中HER2-positive乳腺癌的HER2异质性和治疗反应相关特征

2024-02-012
OAAI
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer

TBCRC 039: 术前ruxolitinib联合或不联合紫杉醇治疗三阴性炎性乳腺癌的II期研究

2024-01-314
OAAI
Heterogeneity and transcriptional drivers of triple-negative breast cancer
2023-12-015
OAAI
Peripheral blood TCR clonotype diversity as an age- associated marker of breast cancer progression

外周血TCR克隆型多样性作为乳腺癌进展的年龄相关标志物

2023-11-274
OAAI